

Title (en)
TGF-BETA INHIBITORS AND THERAPEUTIC USE THEREOF

Title (de)
TGF-BETA INHIBITOREN UND DEREN THERAPEUTISCHE VERWENDUNG

Title (fr)
INHIBITEURS DE TGF-BÊTA ET LEUR UTILISATION THÉRAPEUTIQUE

Publication
EP 4348260 A2 20240410 (EN)

Application
EP 22733495 A 20220603

Priority

- US 202163202260 P 20210603
- US 202163221588 P 20210714
- US 202163221843 P 20210714
- US 202163256927 P 20211018
- US 202263298128 P 20220110
- US 202263302999 P 20220125
- US 202263313355 P 20220224
- US 202263313386 P 20220224
- US 2022022063 W 20220325
- US 2022032278 W 20220603

Abstract (en)
[origin: WO2022256723A2] The present disclosure provides TGFβ inhibitor therapy for treating immunosuppressive conditions, cancer, and fibrosis, either as a monotherapy or combination/adjunct therapy. Selection of suitable therapy and patients who are likely to benefit from such therapy are also disclosed, as well as methods of treating cancer and fibrosis and methods of predicting and monitoring therapeutic response. Related compositions, methods and therapeutic use are also disclosed.

IPC 8 full level
G01N 33/574 (2006.01); **A61K 39/39** (2006.01); **A61K 39/395** (2006.01); **A61P 35/00** (2006.01); **C07K 16/22** (2006.01); **G01N 33/569** (2006.01)

CPC (source: EP)
A61P 35/00 (2018.01); **C07K 16/22** (2013.01); **A61K 2039/505** (2013.01); **A61K 2039/545** (2013.01)

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)
BA ME

Designated validation state (EPC)
KH MA MD TN

DOCDB simple family (publication)
WO 2022256723 A2 20221208; WO 2022256723 A3 20230105; EP 4348260 A2 20240410

DOCDB simple family (application)
US 2022032278 W 20220603; EP 22733495 A 20220603